Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Metabolic Medicine · Hepatic Glycogen Storage Disease

Managing the Liver: Types I, III, and IV

At a Glance

Hepatic Glycogen Storage Diseases (GSD Types I, III, and IV) impair the liver's ability to regulate blood sugar. Management requires strict blood sugar monitoring with CGMs and raw cornstarch therapy to prevent severe hypoglycemia, alongside routine screening for liver and muscle complications.

Hepatic Glycogen Storage Diseases (GSDs) primarily affect the liver’s ability to act as a sugar-release center for the body. While Types I, III, and IV share the name GSD, they each present unique challenges for parents and caregivers.

GSD Type I: The “Sugar-Release” Block

GSD Type I is the most common hepatic form. It occurs because the body lacks the enzyme or transporter needed to release glucose into the bloodstream [1].

  • Type Ia: Caused by a missing enzyme (G6Pase). Children face severe low blood sugar (hypoglycemia) very quickly after eating [2][3].
  • Type Ib: Caused by a missing transporter (G6PT). In addition to low blood sugar, these children have a unique challenge: neutropenia (low white blood cell counts) [4][5]. This makes them highly susceptible to infections and inflammatory bowel disease (IBD) [6][7].

The Empagliflozin Breakthrough: Historically, Type Ib neutropenia was difficult to treat. Recently, a medication called empagliflozin (originally for diabetes) has been repurposed. It works by clearing a toxic sugar byproduct (1,5-AG) from the blood that poisons white blood cells [8][9]. For many, this has normalized blood counts and healed painful mouth sores or IBD symptoms [10][11].

GSD Type III (Cori Disease): Liver and Muscle

Unlike Type I, GSD III affects both the liver and the muscles, including the heart [12].

  • The Liver: Children often have an enlarged liver and low blood sugar, though the hypoglycemia is usually less severe than in Type I [13].
  • The Muscles: Over time, glycogen builds up in muscle tissue, which can lead to muscle weakness (myopathy) and heart thickening (cardiomyopathy) in adulthood [14][15].

GSD Type IV (Andersen Disease): The Fibrosis Risk

GSD Type IV is rare and differs because it produces “abnormal” glycogen that the body treats like a foreign object [16]. Unlike Types I and III, hypoglycemia is not usually the primary or most dangerous symptom. Instead, the abnormal glycogen causes significant inflammation, leading to liver scarring (fibrosis) and potentially cirrhosis (permanent scarring) early in life [17][18].

Essential Tools for Safety

Managing these conditions requires constant vigilance to keep blood sugar stable.

  • Continuous Glucose Monitoring (CGM): This is now considered an essential tool [19]. It provides real-time data to catch “hidden” sugar drops before they become emergencies and helps parents fine-tune the timing and dose of cornstarch [20][21].
  • Cornstarch Therapy: Uncooked cornstarch acts as a slow-release “timed-release” sugar source to prevent crashes during the night or between meals [22].
    • CRITICAL SAFETY WARNING: Do not heat the cornstarch or mix it with hot liquids. Heating cooks the starch and destroys its slow-release properties, which can lead to a dangerous blood sugar crash.
    • INFANT WARNING: Uncooked cornstarch is contraindicated for infants under 6 to 8 months of age. Young infants lack the pancreatic enzyme (amylase) needed to digest it, leading to severe gastrointestinal distress, bacterial fermentation, and paradoxical hypoglycemia [23]. Only initiate this under the strict guidance of a specialized metabolic dietitian.
  • Emergency “Sick Day” Protocols: Common childhood illnesses like a stomach bug can be life-threatening if a child cannot keep cornstarch down. You must have a formal “Sick Day Protocol” and carry an emergency medical letter to present at the ER for immediate IV glucose if oral intake fails [24].

Long-Term Watchlist

As children with hepatic GSD grow, the medical team will monitor for specific complications:

  1. Liver Adenomas: These are benign (non-cancerous) tumors that can develop in the liver, particularly in Type I and Type III [25][26]. In some cases, they can become cancerous, so regular ultrasounds or MRIs are vital [27].
  2. Kidney Health: GSD I carries a risk of kidney stress over time, which may start with high filtration rates and progress to protein in the urine [3][24].
  3. Heart & Muscle: For GSD III and IV, regular heart checks (echocardiograms) are necessary to monitor for any thickening of the heart muscle [28][29].

Common questions in this guide

Why is uncooked cornstarch used for Glycogen Storage Disease?
Uncooked cornstarch acts as a slow-release sugar source to prevent dangerous blood sugar drops between meals and overnight. It must never be heated, as heat destroys its slow-release properties and can lead to a blood sugar crash.
At what age can a baby with GSD start cornstarch therapy?
Uncooked cornstarch should not be given to infants under 6 to 8 months of age. Young babies lack the necessary pancreatic enzymes to digest it, which can cause severe stomach issues and paradoxical low blood sugar.
What is the purpose of empagliflozin for GSD Type Ib?
Empagliflozin helps treat the low white blood cell counts associated with GSD Type Ib. It works by clearing a toxic sugar byproduct from the blood, which helps heal painful mouth sores and improve immune function.
Why do I need a sick day protocol for GSD?
A sick day protocol is a formal emergency plan for when a child cannot keep food or cornstarch down due to illnesses like a stomach bug. It ensures caregivers know exactly when to go to the emergency room for immediate IV glucose to prevent life-threatening blood sugar drops.
Why are regular liver ultrasounds needed for GSD Types I and III?
Routine liver imaging is crucial to monitor for liver adenomas, which are benign tumors that can develop in Types I and III. Regular monitoring ensures any concerning changes are caught early before they can become cancerous.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific blood sugar emergency threshold?
  2. 2.What is the exact ratio of cornstarch to fluid I should be using?
  3. 3.How often should we be doing liver ultrasounds or MRIs to screen for adenomas?
  4. 4.For GSD Ib, are we monitoring the 1,5-AG levels to see how well the empagliflozin is working?
  5. 5.How can we use our CGM data to adjust our child's cornstarch schedule?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (29)
  1. 1

    Efficacious genome editing in infant mice with glycogen storage disease type Ia.

    Arnson B, Ilich E, von Beck T, et al.

    JCI insight 2025; (10(18)).

    PMID: 40762955
  2. 2

    Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia.

    Arnson B, Kang HR, Brooks ED, et al.

    Molecular therapy. Methods & clinical development 2023; (29()):108-119 doi:10.1016/j.omtm.2023.03.001.

    PMID: 37021039
  3. 3

    [Advances on the management of renal lesion in glycogen storage disease type I].

    Wu WC, Wang JS

    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 2021; (29(1)):75-78 doi:10.3760/cma.j.cn501113-20201230-00687.

    PMID: 33541027
  4. 4

    Structural basis of G6P/Pi transport and inhibition in SLC37A4.

    Zhou D, Zhang Y, Chen N, et al.

    Nature structural & molecular biology 2025; doi:10.1038/s41594-025-01711-5.

    PMID: 41225049
  5. 5

    A novel SLC37A4 missense mutation in GSD-Ib without hepatomegaly causes enhanced leukocytes endoplasmic reticulum stress and apoptosis.

    Xu Q, Tang H, Duan L, et al.

    Molecular genetics & genomic medicine 2021; (9(1)):e1568 doi:10.1002/mgg3.1568.

    PMID: 33280276
  6. 6

    Lactylation-driven ALKBH5 diminishes macrophage NLRP3 inflammasome activation in patients with G6PT deficiency.

    Su Z, Lan J, Wang Y, et al.

    The Journal of allergy and clinical immunology 2025; (155(6)):1783-1799.e8 doi:10.1016/j.jaci.2025.01.028.

    PMID: 39900266
  7. 7

    Gastrointestinal complications of hepatic glycogen storage disease: a national survey questionnaire study in China.

    Zhang X, Su Z, Wu J, et al.

    Orphanet journal of rare diseases 2025; (20(1)):41 doi:10.1186/s13023-025-03570-1.

    PMID: 39875987
  8. 8

    Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin.

    Kaczor M, Malicki S, Folkert J, et al.

    Blood advances 2024; (8(11)):2790-2802 doi:10.1182/bloodadvances.2023012403.

    PMID: 38531056
  9. 9

    Hypercalcemia and co-occurring TBX1 mutation in Glycogen Storage Disease Type Ib: case report.

    Kasmi Z, Ain El Hayat I, Aadam Z, et al.

    BMC medical genomics 2025; (18(1)):5 doi:10.1186/s12920-024-02057-5.

    PMID: 39773724
  10. 10

    Safety of SGLT-2 inhibitors in patients with glycogen storage disease type Ib and their efficacy in treating disease-associated digestive symptoms and disorders.

    Chen Z, Sun Z, Li G, Bu H

    Acta diabetologica 2026; (63(4)):629-644 doi:10.1007/s00592-025-02627-8.

    PMID: 41603948
  11. 11

    Effect of empagliflozin treatment on laboratory and clinical findings of patients with glycogen storage disease type Ib: first study from Türkiye.

    Köse E, Özçay F, Aydın Hİ, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(4)):391-398 doi:10.1515/jpem-2024-0556.

    PMID: 40009407
  12. 12

    A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

    Hijazi G, Paschall A, Young SP, et al.

    Molecular genetics and metabolism reports 2021; (29()):100821 doi:10.1016/j.ymgmr.2021.100821.

    PMID: 34820282
  13. 13

    A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.

    Lim JA, Choi SJ, Gao F, et al.

    Molecular therapy. Methods & clinical development 2020; (18()):240-249 doi:10.1016/j.omtm.2020.05.034.

    PMID: 32637453
  14. 14

    Muscle Ultrasound in Patients with Glycogen Storage Disease Types I and III.

    Verbeek RJ, Sentner CP, Smit GP, et al.

    Ultrasound in medicine & biology 2016; (42(1)):133-42.

    PMID: 26437929
  15. 15

    Polyglucosan storage disease in a black-capped parrot (Pionitesmelanocephalus).

    Fiddes KR, Magnotti J, Armien AG, LaDouceur EEB

    Journal of comparative pathology 2025; (216()):20-24 doi:10.1016/j.jcpa.2024.11.003.

    PMID: 39657409
  16. 16

    The potential of dietary treatment in patients with glycogen storage disease type IV.

    Derks TGJ, Peeks F, de Boer F, et al.

    Journal of inherited metabolic disease 2021; (44(3)):693-704 doi:10.1002/jimd.12339.

    PMID: 33332610
  17. 17

    Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model.

    Koch RL, Kiely BT, Choi SJ, et al.

    JCI insight 2024; (9(12)).

    PMID: 38912588
  18. 18

    Glycogen Storage Disease in Twins: When Two Lives Reflect One Silent Battle.

    Shah RK, Khan SA, Devkota D, et al.

    Clinical case reports 2026; (14(1)):e71889 doi:10.1002/ccr3.71889.

    PMID: 41567525
  19. 19

    Personalized management of hepatic glycogen storage disorders: The role of continuous glucose monitoring.

    Gupta A, Agarwala A, Kalaivani M, et al.

    Journal of pediatric gastroenterology and nutrition 2025; (80(1)):151-162 doi:10.1002/jpn3.12391.

    PMID: 39487091
  20. 20

    A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management.

    Peeks F, Hoogeveen IJ, Feldbrugge RL, et al.

    Journal of inherited metabolic disease 2021; (44(5)):1136-1150 doi:10.1002/jimd.12383.

    PMID: 33834518
  21. 21

    [The application of continuous glucose monitoring in the management of hepatic glycogen storage disease].

    Du CQ, Wei H, Zhang C, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2021; (59(6)):452-458 doi:10.3760/cma.j.cn112140-20210321-00235.

    PMID: 34102817
  22. 22

    A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net.

    Rossi A, Hoogeveen IJ, Lubout CMA, et al.

    Journal of inherited metabolic disease 2021; (44(5)):1124-1135 doi:10.1002/jimd.12386.

    PMID: 33844307
  23. 23

    Pancrelipase as Adjunctive Therapy in Severe SCOT Deficiency: A Case of a Novel OXCT1 Gene Deletion.

    Hamdeh MA, Jaber L, Abdullah J, et al.

    JIMD reports 2025; (66(3)):e70024 doi:10.1002/jmd2.70024.

    PMID: 40406160
  24. 24

    Kidney involvement in glycogen storage disease type I: Current knowledge and key challenges.

    Schumann A, Garbade SF, Beblo S, et al.

    Molecular genetics and metabolism 2025; (144(3)):109054 doi:10.1016/j.ymgme.2025.109054.

    PMID: 39954548
  25. 25

    "Bull's eye" appearance of hepatocellular adenomas in patients with glycogen storage disease type I - atypical magnetic resonance imaging findings: Two case reports.

    Vernuccio F, Austin S, Meyer M, et al.

    World journal of clinical cases 2021; (9(4)):871-877 doi:10.12998/wjcc.v9.i4.871.

    PMID: 33585634
  26. 26

    Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease.

    Oterdoom LH, Verweij KE, Biermann K, et al.

    Journal of gastrointestinal and liver diseases : JGLD 2015; (24(4)):515-8 doi:10.15403/jgld.2014.1121.244.had.

    PMID: 26697579
  27. 27

    Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study.

    Jang HJ, Yang HR, Ko JS, et al.

    Journal of Korean medical science 2020; (35(1)):e5 doi:10.3346/jkms.2020.35.e5.

    PMID: 31898434
  28. 28

    Cardiovascular involvement in glycogen storage diseases.

    Pinós T, Cubbon RM, Santalla A, et al.

    Nature reviews. Cardiology 2026; (23(1)):39-59 doi:10.1038/s41569-025-01171-w.

    PMID: 40473899
  29. 29

    A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum.

    Kiely BT, Koch RL, Flores L, et al.

    Frontiers in genetics 2022; (13()):992406 doi:10.3389/fgene.2022.992406.

    PMID: 36176296

This page provides educational information on managing hepatic GSD in children. Always consult your specialized metabolic dietitian and medical team before altering cornstarch therapy, diet plans, or sick day protocols.

Get notified when new evidence is published on Glycogen storage disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.